Androgen profile in patients with polycystic ovary syndrome and its association with metabolic dysfunction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To optimize the diagnosis of biochemical hyperandrogenism (HA) and investigate its association with metabolic dysfunction in polycystic ovary syndrome (PCOS). Materials and methods. The study comprised 437 women with PCOS and 160 healthy women. Clinical and laboratory evaluation consisted of pelvic ultrasonography (USG), analysis of androgen profile including serum levels of total testosterone, free testosterone, and androstenedione (TT, FT, A4), a two-hour glucose tolerance test (GTT) with monitoring of glucose and insulin levels, and the blood lipid prof ile. Results. Measuring a complete serum androgen prof ile increases the detection rate of biochemical HA from 37.4 to 66.4%. The greatest contribution to the diagnosis of HA is made by determining serum A4 concentrations, which are elevated in every second patient with PCOS. HA with co-elevated serum TT and A4 is associated with a 1.5-2 fold increase in the rate of impaired glucose tolerance (IGT), hyperinsulinemia (HI), insulin resistance (IR), and dyslipidemia. Conclusion. Patients with suspected PCOS should be tested for serum TT, FT, and A4; the measurement of A4 is most important. Co-elevated serum TT and A4 may be a useful predictor of developing IR, HI, IGT, and dyslipidemia.

Full Text

Restricted Access

About the authors

G. E Chernukha

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: c-galinal@yandex.ru

A. A Naidukova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: aleeshka@mail.ru

M. A Udovichenko

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: mariia9ll@yahoo.com

E. K Kaprina

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: kaprina_elena@mail.ru

T. Yu Ivanets

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: t_ivanets@oparina4.ru

References

  1. Azziz R., Sanchez L.A., Knochenhauer E.S., Moran C., Lazenby J., Stephens K.C., Taylor K., Boots L.R. Androgen Excess in Women: Experience with Over 1000 Consecutive Patients. JCEM. 2004; 89(2): 453-462. https://doi.org/10.1210/ jc.2003-031122
  2. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. doi: 10.1016/j. fertnstert.2003.10.004
  3. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., Witchel S.F.; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006; 91(11): 4237-45. doi: 10.1210/jc.2006-0178
  4. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Franks S., Gambineri A., Kelestimur F., Macut D., Micic D., Pasquali R., Pfeifer M., Pignatelli D., Pugeat M., Yildiz B.; ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171(4): P1-29. doi: 10.1530/EJE-14-0253
  5. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91:456-88. doi: 10.1016/j.fertnstert.2008.06.035)
  6. Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., Piltonen T., Norman R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 33(9): 1602-18. doi: 10.1093/ humrep/dey256
  7. Jones H., Sprung V.S., Pugh C.J., Daousi C., Irwin A., Aziz N., Adams V.L., Thomas E.L., Bell J.D., Kemp G.J., Cuthbertson D.J. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic pcos phenotypes and healthy controls, independent of obesity and insulin resistance. J. Clin Endocrinol Metab. 2012; 97(10): 3709-16. doi:10.1210/ jc.2012-1382
  8. Чернуха Г.Е., Блинова И.В., Купрашвили М.И. Эндокринно-метаболические характеристики больных с различными фенотипами синдрома поликистозных яичников. Акушерство и гинекология. 2011; 2: 70-76.
  9. Cakir E1, Dogan M., Topaloglu O., Ozbek M., Cakal E., Vural MG, Yeter E., Delibasi T. Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism. Atherosclerosis. 2013; 226: 291-295. doi: 10.1016/j. atherosclerosis.2012.11.004.
  10. Lerchbaum E., Schwetz V., Rabe T., Giuliani A., Obermayer-Pietsch B. Hyperandrogenemia in Polycystic Ovary Syndrome: Exploration of the Role of Free Testosterone and Androstenedione in Metabolic Phenotype. PLoS One. 2014; 9(10): e108263. doi: 10.1371/journal.pone.0108263
  11. Georgopoulos N.A., Papadakis E., Armeni A.K., Katsikis I., Roupas N.D., Panidis D. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens). 2014; 13(2): 213-21. doi: 10.1007/BF03401335
  12. Ruan X., Li M., Mueck A.O. Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management? Curr Pharm Des. 2018; 24(39): 4685-92. doi: 10.2174/1381612825666190130104922
  13. Zhu S., Zhang B., Jiang X., Li Z., Zhao S., Cui L., Chen Z.J. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019; 111 (1): 168-177. doi: 10.1016/ j.fertnstert.2018.09.013
  14. Ананьев Е.В. Синдром поликистозных яичников и беременность. Акушерство и гинекология. 2017; 9: 5-11. [Ananyev E.V. Polycystic ovary syndrome and pregnancy.Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (9): 5-11. (in Russian)]. http://dx.doi.org/10.18565/ aig.2017.9.5-11
  15. Ciaraldi T.P., Aroda V., Mudaliar S., Chang R.J., Henry R.R. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J. Clin. Endocrinol. Metab. 2009; 94(1): 157-63. DOI: 10.1210/ jc.2008-1492
  16. Hojlund K., Glintborg D. Andersen N.R., Birk J.B., Treebak J.T., Frosig C., Beck-Nielsen H., Wojtaszewski J.F. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes. 2008; 57(2):357-66. doi: 10.2337/db07-0706
  17. O’Reilly M.W., Taylor A.E., Crabtree N.J., Hughes B.A., Capper F., Crowley R.K., Stewart P.M., Tomlinson J.W., Arlt W. Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. J. Clin Endocrinol Metab. 2014; 99(3): 1027-36. doi: 10.1210/ jc.2013-3399
  18. Мамедов М.Н., Поддубская Е.А. Диагностика и лечение ранних нарушений углеводного обмена в общетерапевтической практике (методические рекомендации). ФГУ ГНИ ЦПМ. М.; 2011. 36 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies